Fig. 8: The MEIS1-derived peptide exhibits potent inhibitory effects on the oncogenic properties of CRC.

A Cells were treated with MEIS1 peptide at the indicated concentrations, and then the protein level of MEIS1 and p53 were detected. B Cells were treated with MEIS1 peptide at the indicated concentrations, followed by treatment with CHX for various durations. The half-lives of MEIS1 and p53 protein were measured. C Subcutaneous xenografts of cells were harvested from each mouse intraperitoneally injected with PBS or MEIS1 peptide. Scatterplot and curve show the growth and weight of xenografts for each group. D A schematic illustration outlines the pivotal molecular mechanisms that underlie the intricate regulation of the MDM2-p53 axis by MEIS1 in CRC.